Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Billy Smith

Physical Medicine & Rehabilitation Greenville, NC Medical Doctor

NPI 1346275260 CMS profile 106588

2245 Stantonsburg Rd Ste A, Greenville, NC 27834

Open in the dashboard

General payments

$9,621

645 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Billy Smith of Greenville, NC is reported in the CMS Open Payments database as having received $9,621 across 645 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $364 18
2024 General $1,138 62
2023 General $1,682 103
2022 General $1,423 82
2021 General $2,020 143
2020 General $1,306 92
2019 General $1,688 145

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Billy Smith
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Billy Smith were reported at $364. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Billy Smith Physical Medicine & Rehabilitation median Middle half National median
2019 $1,688 $133 $45–$390 $163
2020 $1,306 $88 $29–$272 $114
2021 $2,020 $116 $33–$360 $132
2022 $1,423 $123 $40–$378 $149
2023 $1,682 $131 $43–$396 $160
2024 $1,138 $141 $45–$409 $164
2025 $364 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Collegium Pharmaceutical, Inc. $1,939 204 payments
  2. Forte Bio-Pharma LLC $1,514 29 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $888 55 payments
  4. Scilex Pharmaceuticals Inc. $742 45 payments
  5. AbbVie, Inc. $574 49 payments
  6. RedHill Biopharma Inc. $388 24 payments
  7. Teva Pharmaceuticals USA, Inc. $290 23 payments
  8. Valinor Pharma, LLC $275 16 payments
  9. Indivior Inc. $268 13 payments
  10. Daiichi Sankyo Inc. $253 30 payments
  11. Other $2,489 157 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,529 644 payments
  2. Education $91 1 payment
Products named General payments · program years 2019–2025
  1. XTAMPZA $1,846 196 payments
  2. NALOCET Pain $973 27 payments
  3. PROLATE Pain $847 26 payments
  4. PROLATE Pain $847 26 payments
  5. PROLATE Pain $847 26 payments
  6. PROLATE Pain $847 26 payments
  7. RELISTOR $724 46 payments
  8. ZTLido $589 34 payments
  9. NALOCET Pain $542 2 payments
  10. PROLATE Pain $542 2 payments
  11. Other $5,980 395 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,640

Median for General Practice: 1,105

Drug cost

$422,474

Median for General Practice: $48,734

Branded share of claims

46.5%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 174 $155,000
Oxycontin Oxycodone Hcl Brand 105 $97,089
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 373 $38,809
Oxymorphone Hcl Er Oxymorphone Hcl Brand 43 $30,666
Ozempic Semaglutide Brand 19 $18,882
Oxycodone Hcl Generic 703 $14,435
Movantik Naloxegol Oxalate Brand 24 $9,786
Fentanyl Generic 91 $9,443
Ztlido Lidocaine Brand 18 $8,570
Linzess Linaclotide Brand 14 $8,563

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$76,631

Medicare's payments for the services billed

Medicare patients

355

Average age 65

Services billed

1,411

219 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 39%
Depression 39%
Ischemic heart disease 30%
COPD 29%
Chronic kidney disease 25%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOVANTIK
  • Valinor Pharma, LLC $215
$215 24 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $187
$187 174 —
PROLATE
  • Forte Bio-Pharma LLC $159
$159 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $152
$152 18 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

645 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record